Friday, 13 Jul 2018

You are here

Lyrica Fails in Sciatica Pain

Lyrica (pregabalin) was first approved in 2004 and since has been studied and approved for use in neuropathic pain (associated with diabetic neuropathy), postherpetic neuralgia, partial onset seizures, fibromyalgia and neuropathic pain with spinal cord injury. It is often used to manage chronic pain and neuropathic pain outside these indications.

Australian investigators published their findings in the NEJM last week showing that pregabalin was no better than placebo in treating leg pain associated with sciatics (acute or chronic). 

Patients (n=209) were randomized to either pregabalin at a dose of 150 mg per day (max adjusted to 600 mg per day) or placebo for 8 weeks. The primary outcome was the leg-pain using a 10-point scale at weeks 8 and 52. They also examined disability, back-pain intensity, and quality-of-life measures. Secondary measures demonstrated the same lack of effect.

There were 227 adverse events in the pregabalin group and 124 in the placebo group. Dizziness was more common in the pregabalin group than in the placebo group.

Pregabalin did not sufficiently reduce the leg pain of sciatica, short term or long term and was associated with a higher adverse event rate. 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Weight Loss Lessens Knee Pain in Obese

Obese knee osteoarthritis (OA) patients who lose > 20% of their weight were in significantly less pain, had better function and improved quality of life. 

Blacks Suffer When Pain is Poorly Defined

Racial discrimination was a key feature at a 2-day summit on pain management and the opioid crisis, hosted by the National Institutes of Health on Thursday and Friday.

Asheley Cockrell Skinner, PhD, of the Duke Clinical Research Institute in Durham, North Carolina, provided a broad overview of racial bias in opioid prescribing.

Prescription Drug Monitoring Programs Fail to Deter Opiate Abuse

A systematic review of prescription drug monitoring programs (PDMPs), advocated in the president's Prescription Drug Abuse Prevention Plan, fails to show evidence of efficacy in preventing nonfatal and fatal overdoses.

Measures of Opioid Misuse Predict Future Opioid Overdose and Death

The current issue of Annals of Internal Medicine examines patterns of potential opioid misuse that are associated with subsequent adverse outcomes nationally.

Researchers analyzed a 5% sample of Medicare beneficiaries who had an opioid prescription, without a cancer diagnosis.  Specifically the sought to correlate a diagnosis of opioid overdose with other measures of opioid misuse including:

Opioid Marketing & Meals Tied to Opioid Prescribing

A current study in JAMA Internal Medicine showed that while US physicians who received no opioid-related marketing payments had fewer opioid prescriptions in 2015 compared with 2014, those receiving such payments wrote for more opioid in 2015.